Michael J. Rosen, MD, MSCI

Attending Physician, Division of Gastroenterology, Hepatology and Nutrition

Physician, Schubert-Martin Inflammatory Bowel Disease Center

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-803-7044

Email michael.rosen@cchmc.org


Inflammatory bowel disease


Inflammatory bowel disease; intestinal mucosal immunology

Michael J. Rosen, MD, MSCI, focuses his career on the clinical care of children with inflammatory bowel disease (IBD), and to research aimed at better understanding the causes of chronic inflammation in childhood IBD. The primary focus of Dr. Rosen's laboratory is on the contribution of Type 2 (Th2) inflammation to pediatric colitis. Studies from Dr. Rosen’s lab have demonstrated increased mucosal activation of STAT6, a key Th2 cellular signaling protein, in children with ulcerative colitis and shown a role for STAT6 in perpetuating inflammation in a mouse model similar to ulcerative colitis. 

Dr. Rosen is currently funded by the National Institutes of Health (NIH) to study the expression of genes related to Th2 inflammation in colon tissue form a large cohort of children with IBD.  In addition, his laboratory is conducting ongoing studies with transgenic animal models to determine the mechanisms by which proteins important in perpetuating Th2 inflammatory responses contribute to inflammation in colitis. 

Dr. Rosen serves on the National Pediatric Affairs Committee for the Crohn's & Colitis Foundation of America (CCFA).  His a past recipient of the Fellow to Faculty Transition Award in IBD and the George Ferry Young Investigator Award from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).

MD: Harvard Medical School, Boston, MA, 2003.

Residency: Boston Combined Residency Program in Pediatrics (Boston Children's Hospital and Boston Medical Center), Boston, MA, 2003-2006.

Fellowship: Pediatric Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center and the Monroe Carell, Jr. Children's Hospital at Vanderbilt, Nashville, TN, 2006-2009.

Masters of Science in Clinical Investigation (MSCI): Vanderbilt University School of Medicine, Nashville, TN, 2009.

Certification: Pediatrics, 2007; Pediatric Gastroenterology, Hepatology and Nutrition, 2009.

View PubMed Publications

Lu N, Lieu L, Van Kaer L, Washington MK, Rosen MJ, Dubé P, Wilson KT, Ren X, Hao X Polk DB, Yan F. Activation of the EGFR in macrophages regulates cytokine production and experimental colitis. The Journal of Immunology. 2014; 192(3):1013-23.

Falaiye TO, Mitchell KR, Lu Z, Saville BR, Horst SN, Moulton DE, Schwartz DA, Wilson KT, Rosen MJ. Outcome following infliximab therapy for pediatric patients hospitalized with refractory colitis-predominant inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. 2014; 58(2):213-9.

Rosen MJ*, Chaturvedi R, Washington MK, Kuhnhein LA, Moore PD, Coggeshall SS, McDonough EM, Weitkamp JH, Singh AB. Coburn LA, Williams CS, Van Kaer L, Peebles RS, Wilson KT. STAT6 activation intensifies disease severity while increasing expression of claudin-2 and Th2-inducing cytokines in murine oxazolone colitis. The Journal of Immunology. 2013; 190(4):1849-1858.

Weitkamp JH, Koyama T, Rock MT, Correa H, Goettel J Matta P, Oswald-Richter K, Rosen MJ, Engelhardt BG, Moore D, Polk DB. Diminished mucosal regulatory (FOXP3+) / effector (CD4+, CD8+) T cell ratios as evidence for disrupted immune regulation in necrotizing enterocolitis. Gut. 2013; 62(1):73-82.

Rosen MJ, Denson LA, Kugathasan S. Commentaries on "Workshop report: developing a pediatric inflammatory bowel diseases network and data platform in Canada": pediatric inflammatory bowel disease networks: raising the bar. Journal of Pediatric Gastroenterology and Nutrition. 2012 Aug;55(2):121-2.

Rosen MJ*, Frey MR, Washington MK, Chaturvedi R, Kuhnhein LA, Matta P, Revetta F, Wilson KT, Polk DB. STAT6 activation in ulcerative colitis: A new target for prevention of IL-13-induced colonic epithelial cell dysfunction. Inflammatory Bowel Diseases. 2011; 17(11):2224-2234.

Rosen MJ, Schwartz DA. 31 Year-old with Colitis and Perianal Disease. Clinical Gastroenterology and Hepatology. 2010;8(1):10-4.

Rosen MJ, Moulton DE, Koyama T, Morgan WM, Morrow SE, Herline AJ, Muldoon RL, Wise PE, Polk DB, Schwartz DA. Endoscopic Ultrasound to Guide the Combined Medical and Surgical Management of Pediatric Perianal Crohn’s Disease. Inflammatory Bowel Diseases. 2010; 16(3):461-8.

Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut. 2004;53:1117-1122.

Sands BE, Arsenault JE, Rosen MJ, et al. Risk of Early Surgery for Crohn's Disease: Implications for Early Treatment Strategies. American Journal of Gastroenterology. 2003;98(12):2712-2718.

Th2 Cytokines and Signaling in Pediatric Inflammatory Bowel Disease. Principal Investigator. National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK). Mar 2013-Mar 2018.

Myeloid Cell-Derived IL-33 in Chronic IL-10-Deficient Colitis. Principal Investigator. Cincinnati Children's Research Foundation. Jul 2014-Jun 2016.